RADX (Radiopharm Theranostics) Tariff Resilience Score: 5/10 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RADX Radiopharm Theranostics Ltd RADX
33 GF Score
Price $2.08
GF Value $2.34
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Radiopharm Theranostics Tariff Resilience Score?

Radiopharm Theranostics RADX -1.42% 33 Tariff Resilience Score is 5 as of Sep. 09, 2026. GuruFocus rates RADX with a GF Score™ of 33/100 and a GF Value™ of $2.34 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,358 Biotechnology companies, Radiopharm Theranostics ranks better than 62.37% on this metric.

Radiopharm Theranostics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Radiopharm Theranostics has Biotech firm with potential exposure to tariffs on medical equipment and raw materials. Niche market may offer some pricing flexibility.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Radiopharm Theranostics might have Average Resilient.

Radiopharm Theranostics  (NAS:RADX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Radiopharm Theranostics Tariff Resilience Score Related Terms

RADX vs VRTX, REGN, MRNA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Radiopharm Theranostics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Tariff Resilience Score falls into.


RADX
33GF Score
Radiopharm Theranostics Ltd RADX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Radiopharm Theranostics (RADX) has a Tariff Resilience Score of 5 as of Sep. 09, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Radiopharm Theranostics ranks #511 out of 1358 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Radiopharm Theranostics' Tariff Resilience Score too high?
Radiopharm Theranostics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Radiopharm Theranostics' value of 5 is 25% above this industry median. Based on the distribution chart, Radiopharm Theranostics ranks #511 out of 1358 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Radiopharm Theranostics has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Radiopharm Theranostics' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #511 out of 1358 companies for Tariff Resilience Score. This puts Radiopharm Theranostics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Radiopharm Theranostics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,358 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radiopharm Theranostics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiopharm Theranostics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Based on GuruFocus' analysis, Radiopharm Theranostics (RADX) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.34, compared to a current price of $2.08 — trading 11.1% below its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Radiopharm Theranostics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Radiopharm Theranostics (RADX), the current Tariff Resilience Score is 5 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Radiopharm Theranostics (RADX) Overvalued in 2026?

Based on GuruFocus' analysis, Radiopharm Theranostics stock appears to be undervalued. The current stock price of $2.08 is trading 11.1% below its estimated GF Value™ of $2.34. GuruFocus considers Radiopharm Theranostics to be Modestly Undervalued.

Key valuation signals for RADX:

  • Tariff Resilience Score: 5
  • GF Value™: $2.34 vs. price of $2.08 (11.1% below fair value)
  • GF Score™: 33/100 with 6 warning signs
  • Industry Position: 25% above the Biotechnology median (#511 of 1358)

No single metric tells the full story. See the RADX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Radiopharm Theranostics Business Description

Other Exchanges RAD:Australia
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
33GF Score

Get the complete analysis for RADX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price
$2.34
GF Value